Detalhe da pesquisa
1.
No Immunological Interference or Safety Concerns When Adjuvanted Recombinant Zoster Vaccine Is Coadministered With a Coronavirus Disease 2019 mRNA-1273 Booster Vaccine in Adults Aged 50 Years and Older: A Randomized Trial.
Clin Infect Dis
; 77(9): 1238-1246, 2023 11 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37335963
2.
The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE-50 and ZOE-70.
Clin Infect Dis
; 74(8): 1459-1467, 2022 04 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-34283213
3.
Long-term Protection Against Herpes Zoster by the Adjuvanted Recombinant Zoster Vaccine: Interim Efficacy, Immunogenicity, and Safety Results up to 10 Years After Initial Vaccination.
Open Forum Infect Dis
; 9(10): ofac485, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-36299530
4.
An Analysis of Spontaneously Reported Data of Vesicular and Bullous Cutaneous Eruptions Occurring Following Vaccination with the Adjuvanted Recombinant Zoster Vaccine.
Drug Saf
; 44(12): 1341-1353, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34622421